Dermatology | Jotup

Global Medical Aesthetics Market, 2023-2035: Dominance of Minimally Invasive Procedures - North America Leads, Asia-Pacific Shows Promise - ResearchAndMarkets.com

Retrieved on:

Friday, April 5, 2024

The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.

Key Points:

The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.
Presently, more than 200 medical aesthetics companies are engaged in offering various products and devices to fulfill aesthetic requirements of clients.
Additionally, medical aesthetic companies offer all types of invasive, non invasive and minimally invasive solutions to address the requirements of all end users, such as hospitals, medical aesthetic clinic and individuals in home care settings.
North America leads the medical aesthetics market, driven by advanced solutions, established companies, and high demand for cosmetic procedures.

Hims & Hers Appoints Christopher Payne, Seasoned Tech Industry Executive, as Newest Board Member

Retrieved on:

Thursday, April 4, 2024

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Christopher Payne to the company’s Board of Directors.

Key Points:

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Christopher Payne to the company’s Board of Directors.
View the full release here: https://www.businesswire.com/news/home/20240403772620/en/
Payne joins Hims & Hers board of directors to help the company further build on its leadership position within the personalized health and wellness space.
“He has a history of innovating across industries, building trusted brands globally, and evolving businesses to meet shifting customer needs.
Mr. Payne has also held leadership positions at Microsoft and Amazon, and currently serves on the board of directors of Gogo.

Oakview Dermatology Selects FluentStream’s Business Communication Services to Support Its Nine Locations

Retrieved on:

Tuesday, April 2, 2024

Software, Mobile, Wireless, Internet, Professional Services, Data Management, Apps, Applications, Technology, Health Technology, Data Analytics, Practice Management, Other Technology, Health, Dermatology, Patient, HIPAA, Communication, Nursing

Oakview Dermatology has chosen FluentStream to provide business communication services for its nine office locations in Ohio and South Carolina.

Key Points:

Oakview Dermatology has chosen FluentStream to provide business communication services for its nine office locations in Ohio and South Carolina.
Oakview also required a more adaptable communications platform to support an outsourced call center and remote work.
FluentSream’s analytics and training capabilities also give Oakview quantitative data about its customer service to make more informed business decisions.
“FluentStream’s communication services have enabled Oakview to modernize how we operate,” said Mike Croft, director of nonclinical operations at Oakview Dermatology.

DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Monday, April 1, 2024

Biotechnology, Professional Services, Other Health, Health, Pharmaceutical, Oncology, Medical Devices, Surgery, Genetics, Human Resources, Finance, Employment, Dermatology, Compensated emancipation

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that effective March 27, 2024, the Compensation Committee of DermTech’s Board of Directors granted an aggregate of 26,240 restricted stock units to eight new employees under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan.

Key Points:

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that effective March 27, 2024, the Compensation Committee of DermTech’s Board of Directors granted an aggregate of 26,240 restricted stock units to eight new employees under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan.
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously a DermTech employee, as inducements material to the employee’s entering into employment with DermTech, in accordance with Nasdaq Listing Rule 5635(c)(4).
The 26,240 restricted stock units shall vest over 4 years as follows: (i) twenty-five percent of the restricted stock units will vest on March 5, 2025 and (ii) the remaining seventy-five percent of the restricted stock units will vest in equal quarterly installments until fully vested on March 5, 2028, subject to the employee’s continued employment with the Company on these vesting dates.
The restricted stock units are also subject to the terms and conditions of the 2022 Inducement Plan and the terms and conditions of the equity award agreements covering the grants.

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Retrieved on:

Monday, April 1, 2024

Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.

Key Points:

Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.
Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
“We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Hervé Hoppenot, Chief Executive Officer, Incyte.

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, March 29, 2024

Biotechnology, Pharmaceutical, Health, Dermatology, Employment

Incyte (Nasdaq:INCY) announced today that it granted equity inducement awards to Matteo Trotta, the Company’s new Executive Vice President and General Manager of U.S. Dermatology, pursuant to the Company’s 2024 Inducement Stock Incentive Plan.

Key Points:

Incyte (Nasdaq:INCY) announced today that it granted equity inducement awards to Matteo Trotta, the Company’s new Executive Vice President and General Manager of U.S. Dermatology, pursuant to the Company’s 2024 Inducement Stock Incentive Plan.
The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Mr. Trotta received an award of 7,828 restricted stock units (RSUs) and an award of stock options to purchase 21,868 shares of the Company’s common stock, in each case with a grant and vesting commencement date of March 25, 2024.
The stock options have an exercise price of $57.48 per share, which is equal to the closing price of the Company’s common stock on the grant date.

Clinique Launches in the U.S. Amazon Premium Beauty Store

Retrieved on:

Wednesday, March 27, 2024

Clinique marks the first of a select few brands within The Estée Lauder Companies’ portfolio to open a storefront in the U.S. Amazon Premium Beauty store.

Key Points:

Clinique marks the first of a select few brands within The Estée Lauder Companies’ portfolio to open a storefront in the U.S. Amazon Premium Beauty store.
Developed with Clinique’s Guiding Dermatologists, this interactive questionnaire in Amazon Premium Beauty will custom-fit a skincare regimen for Clinique’s consumers, ensuring a simplified and personalized skincare journey, with recommended products available for purchase from Amazon’s Premium Beauty store.
“We are delighted to introduce Clinique to new consumers in the U.S and make it accessible for the beauty-savvy community in the Amazon Premium Beauty store,” said Michelle Freyre, Global Brand President, Clinique.
“Clinique is a beauty brand revered around the world, drawing on a rich heritage of dermatological expertise, and beloved across generations of customers,” said Melis del Rey, G.M., Amazon U.S. Stores Beauty, Baby, and Beauty Technology.

Integrated Dermatology Appoints Nationally Renowned Healthcare Leader Tushar Ramani, M.D. as CEO

Retrieved on:

Tuesday, March 26, 2024

General Health, Health, Practice Management, Other Health, Dermatology, Growth, Information technology, Integration, Ramani, United, Thomas Jefferson University, Physician, Management

Integrated Dermatology, the country’s largest independent dermatology provider, is pleased to announce the appointment of distinguished healthcare leader Tushar Ramani, M.D., as the company's new chief executive officer.

Key Points:

Integrated Dermatology, the country’s largest independent dermatology provider, is pleased to announce the appointment of distinguished healthcare leader Tushar Ramani, M.D., as the company's new chief executive officer.
Ramani brings to Integrated Dermatology a unique combination of clinical expertise gained as a former anesthesiologist, along with entrepreneurial success as the founder and operator of several nationally prominent healthcare service companies.
In his new role, Ramani’s strategic vision will include expanding the company's dermatology partner network, implementing new technologies to enhance support services, and driving innovation while continuing to deliver high-quality dermatology care.
“We are thrilled to have Tushar join the Integrated team and are looking forward to working with him as he leads the Integrated Dermatology team to new heights,” Jeff Queen said.

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Retrieved on:

Monday, March 25, 2024

Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.

Key Points:

Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.
Research and development (R&D) expenses for the fourth quarter of 2023 were $9.2 million, compared with $8.5 million for the same period in 2022.
General and administrative (G&A) expenses for the fourth quarter of 2023 were $3.2 million, compared with $5.2 million for the same period in 2022.
Net cash used in operating activities in the fourth quarter was $5.7 million.

Global Skin Toner Market Analysis Report, 2023-2024 and 2029 - Surging Trend of Diversity and Inclusivity and Accelerating Popularity of Online Shopping and E-Commerce Platforms - ResearchAndMarkets.com

Retrieved on:

Friday, March 22, 2024

Cosmetics, Online Retail, Retail, Skin care, Nicotinamide, COVID-19, Pimple, Research, Female, Dermatology, Woman, Supermarket, Acne, Skin, Mist, Habit, Market, Salicylic acid

The global skin toners market was valued at US$1.31 billion in 2023 and is expected to reach US$1.73 billion by 2029.

Key Points:

The global skin toners market was valued at US$1.31 billion in 2023 and is expected to reach US$1.73 billion by 2029.
The global skin toners market is extremely competitive and consists of various global and regional players.
Looking ahead, the skin toners market is expected to continue its growth trajectory for several reasons.
One notable aspect of the skin toners market is the growing awareness regarding skincare and protection among the millennial population, across the world, in the recent years.